cisplatin, docetaxel

DRUG3 trials

Sponsors

Spanish Lung Cancer Group, European Lung Cancer Working Party, National Guard Health Affairs

Conditions

BRCA1 MutationCarcinoma, Non-Small-Cell LungNon Small Cell Lung CancerNon-small Cell Lung Cancer Metastatic

Phase 2

Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer

SuspendedNCT01356303

National Guard Health AffairsNon-small Cell Lung Cancer Metastatic

Start: 2009-03-31End: 2016-08-31Target: 50Updated: 2016-05-13

Phase 3

Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma

TerminatedNCT00617656

Spanish Lung Cancer GroupBRCA1 Mutation, Non Small Cell Lung Cancer

Start: 2008-02-29End: 2015-04-30Updated: 2024-01-30

Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer

CompletedNCT00622349

European Lung Cancer Working PartyCarcinoma, Non-Small-Cell Lung

Start: 2004-02-29End: 2009-12-31Updated: 2013-01-30

Related Papers

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.

2018-11-2213 citations

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

2014-08-2719 citations

Treatment Based on BRCA1 and RAP80 Does Not Extend PFS

MD Conference Express2013-07-01

Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC).

Journal of Clinical Oncology2013-06-205 citations

Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC).

2013-06-011 citations